Sinovac's COVID-19 vaccine gains China acceptance for emergency use found in children, adolescents
05 June, 2021
China has approved crisis utilization of Sinovac Biotech's COVID-19 vaccine in persons aged between three and 17, its chairman Yin Weidong told state Television set late on Fri (Jun 4).
China's mass vaccination drive, which administered 723.5 million doses of vaccines by Jun 3, is currently only available to those aged 18 and above.
When Sinovac's vaccine will be wanted to younger groups is determined by overall health authorities formulating China's inoculation strategies, Yin told point out TV within an live interview.
Yin said minors have lower priority for vaccination against the coronavirus compared with older people, who face higher threat of extreme symptoms after infection.
Preliminary results from Phase I and II medical trials showed the vaccine could trigger immune response on 3 to 17 year-older participants, and most effects were mild.
State-backed drugmaker Sinopharm, which includes two shots using related technology to Sinovac's product, can be submitting data for clearance on younger groups. A vaccine from CanSino Biologics', adopting a several strategy, has entered a Stage II trial regarding those aged between six and 17.
Sinovac in addition has completed a Phase II clinical trial where individuals were injected with a good third booster medication dosage after completing two regular shots, Yin said.
Participants found 10 fold increase in antibody levels weighed against previous levels in weekly, and 20 fold in two per month, Yin said.
Yin cautioned that Sinovac even so must complete longer-term observation of antibody duration before it can make advice to authorities about whenever a third dose ought to be given.
Source: